Scott M. Rocklage, PhD
Managing Partner

Dr. Rocklage joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over 20 years of healthcare management experience with strategic leadership responsibilities that have resulted in the successful approval of three U.S. New Drug Applications by the FDA (Omniscan™, Teslascan® and Cubicin®), and entered six drug candidates into clinical trials. Dr. Rocklage has served as Chairman & CEO of Cubist Pharmaceuticals, President & CEO of Nycomed Salutar, President, CEO & Chairman of Nycomed Interventional, and has held various R&D positions at Salutar and Catalytica. Dr. Rocklage currently serves as Board Chairman of Achaogen, Relypsa and SteriCoat as well as on the Board of WaveRx, Pulmatrix and Variation and the Board of Associates at the Whitehead Institute. Dr. Rocklage received his BS in Chemistry from the University of California, Berkeley, and his PhD in Chemistry from the Massachusetts Institute of Technology. Dr. Rocklage is based in the Waltham, MA office.